Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone pressurised metered-dose inhaler - Chiesi

Next Previous
X
Search
Drug Profile

Beclometasone pressurised metered-dose inhaler - Chiesi

Alternative Names: BDP Modulite®; Beclazone Modulite; Beclazone Modulite Easi-Breathe; Beclojet 250 HFA; Beclometasone HFA inhalation - Chiesi; Beclometasone Modulite; Beclometasone pMDI; Beclomethasone HFA inhalation - Chiesi; Beclomethasone hydrofluoroalkane inhalation - Chiesi; Beclomethasone Modulite; CHF 781; Clenil Modulite; HFA Beclomethasone Dipropionate

Latest Information Update: 10 Jul 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chiesi Farmaceutici
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma

Most Recent Events

  • 13 Jul 2020 Chiesi Farmaceutici and Bayer entered into a co-promotion agreement for Clenil® for Chronic respiratory diseases in China
  • 29 Jan 2020 Beclometasone pressurised metered-dose inhaler is still in phase II trials for Asthma (Inhalation) is ongoing USA (NCT03084718)
  • 05 Dec 2018 Chiesi Farmaceutici completes the phase II BEAM trial in Asthma in USA (Inhalation) (NCT03084718)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top